<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/79D094C5-AC51-440D-AFFB-4C3DF8C5599F"><gtr:id>79D094C5-AC51-440D-AFFB-4C3DF8C5599F</gtr:id><gtr:firstName>Nishrin</gtr:firstName><gtr:otherNames>Burhanudin</gtr:otherNames><gtr:surname>Spencer</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G84%2F6718"><gtr:id>3FDA0AA5-111D-4C70-B0F2-D29839D50BE5</gtr:id><gtr:title>Compartmentalised Apoptosis in Platelet Formation by Megakaryocytes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G84/6718</gtr:grantReference><gtr:abstractText>Platelets are cells circulating in blood that are essential for the prevention of excessive bleeding when our tissues are injured, forming life-saving plugs (clots) in damaged blood vessels. Patients with low circulating platelet counts are at risk of bleeding but there are no molecular therapies to increase platelet number. I will define new approaches to this problem by defining mechanisms by which a special form of cell death results in formation of platelets from their parent cells in bone marrow, so-called megakaryocytes.</gtr:abstractText><gtr:technicalSummary>By contrast with neutrophils, no means (other than transfusion) exist to increase circulating platelet number in patients with thrombocytopaenia because the mechanisms regulating megakaryocyte (MK) formation of proplatelet extensions and release of platelets have been obscure. My supervisors have recently discovered that these events are driven by caspase-dependent mechanisms that can be triggered by ligation of the Fas death receptor, which results in compartmentalised apoptosis of the MK cell body but not the processes/platelets (J Cell Biol 2003:160,577-87). I aim to:

(i) Define mechanisms conferring selective survival upon the MK proplatelet compartment, testing the functional importance of exclusion of caspases and concentration of Bcl-XL;
(ii) characterise Fas ligand-dependent mechanisms by which bone marrow sinusoidal endothelial cells regulate compartmentalised apoptosis in adjacent MKs; and
(iii) employ cell/bone marrow transplantation models to confirm that ligation of MK Fas in vivo does indeed increase circulating platelet number as indicated by previous ex vivo studies of human bone cores.

These studies will furnish fundamental new insights into platelet production, provide extensive training opportunities in molecular cell biology and may ultimately lead to new approaches towards therapy of thrombocytopaenia (in which thrombopoietin, the cytokine regulating MK division is not effective, by contrast with G-CSF in neutropaenia).</gtr:technicalSummary><gtr:fund><gtr:end>2010-10-27</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-11-28</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>192004</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B4E5565E-A5C4-439F-90B5-030E0555D2A9</gtr:id><gtr:title>Macrophages expressing heme oxygenase-1 improve renal function in ischemia/reperfusion injury.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7871eeac6beee38c1dd69a1e1093f07"><gtr:id>f7871eeac6beee38c1dd69a1e1093f07</gtr:id><gtr:otherNames>Ferenbach DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>GneGZptqqTK</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G84/6718</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>